Articles from Pulmovant, Inc.

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects

By Pulmovant, Inc. · Via GlobeNewswire · June 16, 2025